Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rare molecular subtypes of lung cancer.

Nature reviews. Clinical oncology - 1 Apr 2023

Harada Guilherme, Yang Soo-Ryum, Cocco Emiliano, Drilon Alexander

Abstract excerpt

Oncogenes that occur in ≤5% of non-small-cell lung cancers have been defined as 'rare'; nonetheless, this frequency can correspond to a substantial number of patients diagnosed annually. Within rare oncogenes, less commonly identified alterations (such as HRAS, NRAS, RIT1, ARAF, RAF1 and MAP2K1 mutations, or ERBB family, LTK and RASGRF1 fusions) can share certain structural or oncogenic features with more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36806787
DOI: 10.1038/s41571-023-00733-6
PMCID: PMC10413877

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rare molecular subtypes of lung cancer.PMID 36806787Read ↗

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2Semantic proximity Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.Semantic proximity Read ↗

Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Semantic proximity Read ↗

The Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

Oncogenic driver mutations in lung cancerSemantic proximity Read ↗

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).Semantic proximity Read ↗

Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem CellsSemantic proximity Read ↗

The minority report: targeting the rare oncogenes in NSCLC.Semantic proximity Read ↗

Established, emerging and elusive molecular targets in the treatment of lung cancer.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.